Till­man Gern­gross steers a biotech uni­corn to Nas­daq, while an­oth­er com­pa­ny's IPO plans fiz­zle

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The biotech in­dus­try was set to end this week with an­oth­er two ma­jor pub­lic de­buts. The first com­pa­ny, Till­man Gern­gross’ an­ti­body start­up Ada­gio Ther­a­peu­tics, priced a $300 mil­lion-plus IPO on Thurs­day, bring­ing its val­u­a­tion to around $2 bil­lion. But the sec­ond, WCG Clin­i­cal, fell through on its IPO plans, miss­ing out on a po­ten­tial $720 mil­lion raise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER